Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
about
Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantationThe Daniel K. Inouye College of Pharmacy Scripts: Hepatitis C in 2015: Recent Advancements and Current ChallengesEvaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C VirusLong-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United StatesHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.Response to Liu et al.Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population.Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid PatientsDRUG PRICING & CHALLENGES TO HEPATITIS C TREATMENT ACCESS
P2860
Q28076406-316863D3-79E9-4BB0-B094-AA6045FDD1D5Q28081108-9437CCD9-2AF9-4FCC-9A13-C7C4523F139DQ33879348-95C837EE-2AD9-41D3-A6D3-528CA1B5A640Q36193232-4B3C1E7B-457D-4EC9-ABC1-498719D3A802Q37018850-334A2F78-5434-4E19-8DFA-EBE376B82E9EQ37578288-28CCE1CA-D819-4503-879F-C5003830D116Q38405059-AA11DC50-F561-4476-BDF0-A3C28124F100Q38854076-2961D8BC-89B1-4FE5-A065-427E95234D36Q38916843-86065244-7F5A-43C7-9CFC-8285BBBD5122Q40078226-23CCB591-5C9A-4E11-91EE-B038E7904647Q46257792-5B8E1F57-CDDD-48A6-A06F-33B2DAE0230FQ49824510-3A00E212-27BD-4CBC-88DA-D324ECA946FEQ50131580-018A5F6A-F1ED-4271-B53C-BCF75441FA0BQ55239844-E528134C-3F89-4AB4-9719-7692A3D32EC5Q55517100-D39E3DA1-C5C7-4B56-A304-F4EB27E9D5BDQ57152417-EFDBBAA6-D9CC-4C30-A74F-03A88E78B669Q58774084-3E3911BB-F3D8-4EF8-9AF9-36EDBF5C46FC
P2860
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
type
label
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
prefLabel
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@ast
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@nl
P2093
P2860
P3181
P1433
P1476
Drug Authorization for Sofosbu ...... arrier in the HCV Care Cascade
@en
P2093
AnnMarie Liapakis
Carol Eggers
Claudia Bertuccio
Dana Sapir
Jessica Wright
Joseph K Lim
Kristine Drozd
Yanhong Deng
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0135645
P407
P577
2015-01-01T00:00:00Z